Viveka Nainani

Viveka Nainani

Auto-generated profile, based on publicly available information

Viveka Nainani

Department of Oral & Maxillofacial Surgery, SVS Institute of Medical & Dental Sciences, Mehaboobnagar, TG, India

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2017 in Archives of Disease in Childhood
Verified
Journal Article
Closed access
PDF file
VNViveka Nainani
Viveka Nainani
UGUshma Galal
Ushma Galal
JBJim Buttery
Jim Buttery
MSMatthew D Snape
Matthew D Snape
Objectives To determine whether the introduction of the capsular group B meningococcal vaccine (4CMenB) in the UK has increased presentations of infants to emergency departments with adverse events following immunisation (AEFI). Participants, design and setting A retrospective review of hospital records of infants aged 1–6 months presenting to Oxford University Hospitals NHS Trust’s emergency departments from September 2013 to August 2016 with discharge diagnoses of vaccine reactions or non-specific conditions. Immunisation history was checked by reference to centralised immunisation records. Main outcome measures Presentation classifications were ‘probable vaccine reaction’ (ie, symptoms within 48 hours of immunisation; no alternative cause found), ‘possible vaccine reaction’ (symptoms within 48 hours of immunisation with a possible alternative cause) or ‘not related’ (clear alternative diagnosis or not immunised within previous 48 hours). Results Prior to 4CMenB introduction (2013–15), an annual average of 12 infants presented with probable or possible AEFIs, increasing to 38 infants in the year following 4CMenB introduction (2015/2016). Rates of AEFIs per 1000 immunisation episodes increased post-4CMenB introduction from 1.03 to 3.4 (p<0.001) at 2 months and from 0.14 to 1.13 (p=0.005) at 4 months. At 3 months, when 4CMenB is not given, no increase was seen (p=0.380). 4CMenB introduction was also associated with increased AEFI-related hospital admissions, invasive investigations and intravenous antibiotic use. Conclusions The increase in emergency department attendances, investigations and antibiotic use for AEFIs following 4CMenB immunisation may influence the cost-effectiveness of the 4CMenB immunisation campaign.

1 January 2022 in Journal of Dental Anesthesia and Pain Medicine
Verified
Journal Article
Open access
PDF file
TMTejdeep Muthuluri
Tejdeep Muthuluri
SCSiddardha Gowtam Chandrupatla
Siddardha Gowtam Chandrupatla
RRRitesh Rajan
Ritesh Rajan
VRViveka V. Reddy
Viveka V. Reddy
DJDinesh K. Jhawar
Dinesh K. Jhawar
APAbhinand Potturi
Abhinand Potturi
Muthuluri T, et al. J Dent Anesth Pain Med. 2022 Dec;22(6):443-450. https://doi.org/10.17245/jdapm.2022.22.6.443

1 June 2018 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
LDLuke P. Dawson
Luke P. Dawson
JWJosephine Warren
Josephine Warren
JMJuan Mundisugih
Juan Mundisugih
VNViveka Nainani
Viveka Nainani
WCWilliam Chan
William Chan
JSJames A. Shaw
James A. Shaw